Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Rocon who wrote (12452)	8/1/1998 8:32:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

Ron, Hopefully we will all know something on Monday but I don't care if we have to wait a little longer. VLAD

To: Rocon who wrote (12452)	8/1/1998 9:19:00 PM
From: VLAD	Read Replies (2) \| Respond to of 23519

Ron, FWIW, I think that Vivus can get a lot more for the company if it is sold to both J&J and Astra. Both can maintain their international territories and they can split the US and Japan as they please. I see no reason why each company could not make over $1.00/share in their territories if they market effectively and much more in subsequent years even in the presence of Viagra. If each company pays $10.00/share that gives us $20.00/share for the entire company. Considering the costs to get a new drug developed and on the market I think that if each company paid $10.00/share they would be getting a great bargain since they are buying a turnkey situation with rights to Alibra and other drugs in the R&D stage, They both may even want to keep Vivus intact as a subsidiary for pure R&D since they already have a lab in the corporate office and working relations with various universities. Such negotiations would be complex and require the likes of an investment banker. Maybe that is what Vivus has decided to do and we will hear more on Monday. VLAD